<unk> , sold under the brand name Klisyri, is a medication for the treatment of actinic keratosis on the face or scalp. The most common side effects include local skin reactions, application site pruritus, and application site pain.<unk>  was approved for medical use in the United States in December 2020, and in the European Union in July 2021. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication. It functions as a mitotic inhibitor.
Tirbanibulin
Avatrombopag
Lusutrombopag
Eltrombopag
Hirudin
Ximelagatran
Bivalirudin
Rivaroxaban